KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Invested Capital (2016 - 2025)

Historic Invested Capital for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $73.6 million.

  • Travere Therapeutics' Invested Capital rose 9285.36% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.6 million, marking a year-over-year increase of 9285.36%. This contributed to the annual value of $127.8 million for FY2024, which is 3638.02% down from last year.
  • Travere Therapeutics' Invested Capital amounted to $73.6 million in Q3 2025, which was up 9285.36% from $101.6 million recorded in Q2 2025.
  • Travere Therapeutics' Invested Capital's 5-year high stood at $362.7 million during Q1 2021, with a 5-year trough of $15.1 million in Q2 2024.
  • Moreover, its 5-year median value for Invested Capital was $127.8 million (2024), whereas its average is $167.4 million.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 8772.38% in 2024, then soared by 57066.09% in 2025.
  • Quarter analysis of 5 years shows Travere Therapeutics' Invested Capital stood at $309.5 million in 2021, then plummeted by 83.89% to $49.9 million in 2022, then surged by 302.82% to $200.8 million in 2023, then plummeted by 36.38% to $127.8 million in 2024, then crashed by 42.42% to $73.6 million in 2025.
  • Its last three reported values are $73.6 million in Q3 2025, $101.6 million for Q2 2025, and $101.6 million during Q1 2025.